Pharma Data Congress

September 2-3, 2021 | UK

Take a deep dive into FAIR data, data harmonisation and standardisation. In line with current industry trends, industry experts will discuss implementing enterprise FAIR data lakes and best practices in adopting FAIR data options in pharma. Learn more about data & metadata management, storage and data analytics. Hear presentations covering data management strategies for RWE, storage platform updates and adopting data-led technologies in drug discovery.

Join a focused stream on AI and discuss the adoption of AI technologies in the pharma early drug development pipeline as well as case studies. Delve into genome informatics and learn about integrating genomics with AI initiatives and analysing and mapping genomics data network.

Spotlight

Formulation, process, and analytical development for antibody-drug conjugates, or ADCs, is complex. While the development of an aqueous solution formulation may be preferred over a lyophilized product, it is useful to initially pursue a dual path and develop drug product formulations for both a sterile solution and a freeze-dried solid presentation, ultimately choosing the most successful candidate for final development. An antibody-drug conjugate, or ADC, consists of a monoclonal antibody (mAb) joined to a highly potent or cytotoxic drug by a stable, chemical linker with labile bonds. The antibody is targeted to attach to an antigen on the surface of a tumor cell. Once the connection is made between surface antigen and antibody, the antibody and linked drug are incorporated into the tumor cell. The drug is then cleaved from the antibody, and goes to work to destroy the tumor cell. Once internalized, the amount of “payload drug” required to cause cell death is relatively small. For that reason, ADC’s are generally better tolerated by patients than more traditional forms of chemotherapy.


OTHER PAST CONFERENCES

DIGI-TECH PHARMA And AI 2022

May 10-11, 2022 | USA

The Digi-Tech Pharma & AI 2022 conference brings with it even more interactive sessions, expert speakers, senior professionals and decision makers from leading pharma, bio-tech and healthcare industry.

HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS

May 9-10, 2022 | UK

The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs,

Traditional Medicine Ethnomedicine And Natural Therapies

May 18-19, 2022 | USA

Magnus Group cordially invites you to its “3rd Edition of International Conference on Traditional Medicine, Ethnomedicine and Natural Therapies” which is going to be held Virtually during May 18-19, 2022.

World Congress on Advanced Pharmacy and Clinical Research

May 2, 2022 | Australia

RESEARCH SOCIETY cordially invite you to attend the WCADPHCLRE slated on 2nd-May-2022 at Sydney . We welcome all scientists, scholars, students, industrialists to attend and explore their knowledge in the field of World Congress on Advanced Pharmacy and Clinical Research.

Spotlight

Formulation, process, and analytical development for antibody-drug conjugates, or ADCs, is complex. While the development of an aqueous solution formulation may be preferred over a lyophilized product, it is useful to initially pursue a dual path and develop drug product formulations for both a sterile solution and a freeze-dried solid presentation, ultimately choosing the most successful candidate for final development. An antibody-drug conjugate, or ADC, consists of a monoclonal antibody (mAb) joined to a highly potent or cytotoxic drug by a stable, chemical linker with labile bonds. The antibody is targeted to attach to an antigen on the surface of a tumor cell. Once the connection is made between surface antigen and antibody, the antibody and linked drug are incorporated into the tumor cell. The drug is then cleaved from the antibody, and goes to work to destroy the tumor cell. Once internalized, the amount of “payload drug” required to cause cell death is relatively small. For that reason, ADC’s are generally better tolerated by patients than more traditional forms of chemotherapy.

resources